VTUS Related FDA

Nov 5, 2012 08:03 AM Ventrus Biosciences (VTUS) Receives FDA Written Feedback,

Jun 25, 2012 12:41 PM Cantor Fitzgerald Cuts Rating and Price Target Ventrus Biosciences (VTUS); Phase III Trial Misses; New Exit Strategy Potential Sale

Jun 25, 2012 07:02 AM Ventrus (VTUS) Issues Results from Pivotal Phase 3 Trial of Iferanserin, Says Failed to Show Improvement from Therapy

May 14, 2012 09:42 AM Ventrus Biosciences (VTUS) Higher On Positive Trial Results

Jan 13, 2012 03:01 PM Ventrus BioSciences (VTUS) Publishes Prior Phase 2b Study on the Safety and Efficacy of Iferanserin

Dec 21, 2011 03:03 PM Ventrus BioSciences (VTUS) Announces Completion of Enrollment with Phase 3 Trial of Diltiazem

Jun 22, 2011 08:37 AM FDA Requests More Info from Ventrus (VTUS) for VEN 309 SPA

May 2, 2011 04:41 PM Ventrus BioSciences (VTUS) Adds Third Treatment to Iferanserin Phase III

Mar 18, 2011 04:04 PM Ventrus BioSciences (VTUS) Announces Improved, FDA-Recommended Endpoints Proposed for Phase III Hemorrhoid Study